Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call
26 Fevereiro 2019 - 8:30AM
Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage
biopharmaceutical company innovating treatments for people with
ultra-rare bone disorders and other diseases, today announced that
the company will not report its fourth quarter and year end 2018
financial results on Feb. 28, 2019, and will cancel the associated
conference call and its participation in the 2019 SVB Leerink
Global Healthcare Conference. These cancellations are due to the
Feb. 25, 2019 announcement that Ipsen and Clementia have entered
into a definitive agreement for Ipsen to acquire Clementia.
About Clementia Pharmaceuticals
Inc.Clementia is a clinical-stage company innovating
treatments for people with ultra-rare bone disorders and other
diseases with high medical need. The company is preparing for a
2019 NDA submission to the FDA to seek approval of its lead product
candidate, palovarotene, a novel RARγ agonist, for the prevention
of heterotopic ossification (HO) associated with flare up symptoms
in adults and children with fibrodysplasia ossificans progressiva
(FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional
dosing regimen of palovarotene for the treatment of FOP.
Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the
treatment of multiple osteochondromas (MO), also known as multiple
hereditary exostoses (MHE). In addition, Clementia has commenced a
Phase 1 trial for an eye drop formulation of palovarotene for the
potential treatment of dry eye disease and is also investigating
other conditions that may benefit from RARγ therapy. For more
information, please visit www.clementiapharma.com and connect with
us on Twitter @ClementiaPharma.
Investor/Media Contact:
Joseph WalewiczClementia Pharmaceuticals Inc.+1-514-940-1080
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Clementia Pharmaceuticals Inc. da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de